CY1105556T1 - Χρηση δαπτομυκινης - Google Patents

Χρηση δαπτομυκινης

Info

Publication number
CY1105556T1
CY1105556T1 CY20061100536T CY061100536T CY1105556T1 CY 1105556 T1 CY1105556 T1 CY 1105556T1 CY 20061100536 T CY20061100536 T CY 20061100536T CY 061100536 T CY061100536 T CY 061100536T CY 1105556 T1 CY1105556 T1 CY 1105556T1
Authority
CY
Cyprus
Prior art keywords
daptomycin
muscle toxicity
administering
dosing interval
skeletal muscle
Prior art date
Application number
CY20061100536T
Other languages
English (en)
Inventor
Frederick B. Oleson, Jr.
Francis P. Tally
Original Assignee
Cubist Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26798675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1105556(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cubist Pharmaceuticals, Inc. filed Critical Cubist Pharmaceuticals, Inc.
Publication of CY1105556T1 publication Critical patent/CY1105556T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει μεθόδους χορήγησης θεραπευτικώς δραστικού ποσού δαπτομυκίνης ταυτοχρόνως ελαχιστοποιώντας την τοξικότητα στους σκελετικούς μυς. Οι μέθοδοι έγκεινται σε χορήγηση δαπτομυκίνης με δοσολογικό μεσοδιάστημα 24 ωρών ή και μεγαλύτερο. Αυτό το μακρύ δοσολογικό μεσοδιάστημα ελαχιστοποιεί την τοξικότητα στους σκελετικούς μυς και επιτρέπει την επίτευξη υψηλότερων κορυφαίων συγκεντρώσεων δαπτομυκίνης, οι οποίες κορυφαίες συγκεντρώσεις σχετίζονται με τη δραστικότητα αυτής. Επίσης η εφεύρεση παρέχει μεθόδους χορήγησης λιποπεπτιδικών αντιβιοτικών εκτός της δαπτομυκίνης ταυτοχρόνως ελαχιστοποιώντας την τοξικότητα στους σκελετικούς μυς χορηγώντας θεραπευτικώς δραστικό ποσό του λιποπεπτιδικού αντιβιοτικού με δοσολογικό μεσοδιάστημα το οποίο δεν απολήγει σε τοξικότητα στους μυς. Η εφεύρεση επίσης παρέχει μεθόδους χορήγησης κινουπριστίνης/δαλφοπριστίνης ταυτοχρόνως ελαχιστοποιώντας την τοξικότητα στους σκελετικούς μυς χορηγώντας θεραπευτικώς δραστικό ποσό κινουπριστίνης/δαλφοπριστίνης με δοσολογικό μεσοδιάστημα το οποίο δεν απολήγει σε τοξικότητα στους μυς.
CY20061100536T 1998-09-25 2006-04-18 Χρηση δαπτομυκινης CY1105556T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10182898P 1998-09-25 1998-09-25
US12575099P 1999-03-24 1999-03-24
PCT/US1999/022366 WO2000018419A2 (en) 1998-09-25 1999-09-24 Methods for administration of antibiotics

Publications (1)

Publication Number Publication Date
CY1105556T1 true CY1105556T1 (el) 2010-07-28

Family

ID=26798675

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20061100536T CY1105556T1 (el) 1998-09-25 2006-04-18 Χρηση δαπτομυκινης
CY200600003C CY2006003I2 (el) 1998-09-25 2006-07-18 Χρηση δαπτομυκινης
CY20161101219T CY1118334T1 (el) 1998-09-25 2016-11-24 Χρηση δαπτομυκινης

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY200600003C CY2006003I2 (el) 1998-09-25 2006-07-18 Χρηση δαπτομυκινης
CY20161101219T CY1118334T1 (el) 1998-09-25 2016-11-24 Χρηση δαπτομυκινης

Country Status (26)

Country Link
US (2) US6468967B1 (el)
EP (2) EP1115417B1 (el)
JP (4) JP4184607B2 (el)
KR (2) KR20010075327A (el)
CN (2) CN1150029C (el)
AT (1) ATE322280T1 (el)
AU (1) AU764348B2 (el)
BR (1) BR9914051A (el)
CA (1) CA2344318C (el)
CY (3) CY1105556T1 (el)
DE (3) DE122006000049I2 (el)
DK (2) DK1674107T3 (el)
ES (2) ES2603086T3 (el)
HK (1) HK1040363B (el)
HU (1) HU230656B1 (el)
IS (2) IS5890A (el)
LU (1) LU91254I2 (el)
NL (1) NL300232I2 (el)
NO (1) NO20011454L (el)
NZ (1) NZ510690A (el)
PL (2) PL203689B1 (el)
PT (2) PT1115417E (el)
RU (1) RU2363489C9 (el)
SI (2) SI1115417T1 (el)
TR (1) TR200100841T2 (el)
WO (1) WO2000018419A2 (el)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1115417B1 (en) 1998-09-25 2006-04-05 Cubist Pharmaceuticals, Inc. Use of daptomycin
JP4990456B2 (ja) 1999-12-15 2012-08-01 キュービスト ファーマシューティカルズ， インコーポレイテッド 抗菌剤としてのダプトマイシンアナログ
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
WO2002059145A1 (en) * 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
IL156394A0 (en) * 2000-12-18 2004-01-04 Cubist Pharm Inc Methods for preparing purified lipopeptides
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
EP1932853A1 (en) 2001-08-06 2008-06-18 Cubist Pharmaceutical Inc. Novel depsipeptides and process for preparing same
AU2003274927A1 (en) * 2002-08-23 2004-03-11 Genome Therapeutics Corporation Methods and reagents for preventing bacteremias
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20050277581A1 (en) * 2002-11-18 2005-12-15 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20050220862A1 (en) * 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US20080051326A1 (en) * 2004-11-12 2008-02-28 Alexander Dylan C Antiinfective Lipopeptides
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8546423B2 (en) 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US20070238630A1 (en) * 2006-03-29 2007-10-11 Phillips Douglas H Subcutaneous skin cleanser
EP2018864A1 (en) * 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
KR20100137439A (ko) * 2008-03-04 2010-12-30 엘란 파마 인터내셔널 리미티드 항감염제의 안정성 액체 포뮬레이션 및 항감염제의 조정된 용량투여 요법
PL3338791T3 (pl) 2008-07-17 2020-04-30 Acorda Therapeutics, Inc. Terapeutyczne dawkowanie neureguliny do leczenia lub zapobiegania niewydolności serca
DE102008046610A1 (de) * 2008-09-09 2010-03-11 Biomet Deutschland Gmbh Verwendung einer pharmazeutischen Zusammensetzung zur lokalen Infektionstherapie sowie Medizinprodukt
PL2346509T3 (pl) 2008-10-07 2021-03-08 Horizon Orphan Llc Lewofloksacyna w postaci aerozolu dla zmniejszania stanu zapalnego płuc
KR20110091510A (ko) 2008-10-07 2011-08-11 엠펙스 파마슈티컬즈, 인코포레이티드 약동학 개선을 위한 에어로졸 플루오로퀴놀론 제형
WO2010048630A1 (en) 2008-10-24 2010-04-29 Los Angeles Biomedical Reserch Institute At Harbor-Ucla Medical Center Anti-infective hydroxy-phenyl-benzoates and methods of use
RS53152B (en) * 2008-12-22 2014-06-30 Cubist Pharmaceuticals Inc. NEW ANTIBACTERIAL AGENTS FOR TREATMENT OF Gram POSITIVE INFECTIONS
WO2010075416A1 (en) 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
US8450300B2 (en) * 2009-07-13 2013-05-28 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
CA2767614C (en) * 2009-07-13 2019-01-15 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
SI2473170T1 (sl) 2009-09-04 2019-10-30 Horizon Orphan Llc Uporaba aerosoliziranega levofloksacina za zdravljenje cistične fibroze
LT2504353T (lt) 2009-11-23 2018-09-25 Cubist Pharmaceuticals Llc Lipopeptidų kompozicijos ir susiję būdai
US8247394B2 (en) 2010-06-02 2012-08-21 Cempra Pharmaceuticals Inc. Methods of treating urethritis and related infections using fusidic acid
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
US8461188B2 (en) 2011-10-20 2013-06-11 Trius Therapeutics, Inc. Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
AU2013237939A1 (en) 2012-03-30 2014-10-30 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
US9655946B2 (en) * 2012-09-11 2017-05-23 Hospira Australia Pty Ltd. Daptomycin formulations and uses thereof
CN103006562B (zh) * 2013-01-21 2014-09-17 西南大学 达托霉素醇质体制剂
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
CN109310735A (zh) * 2016-05-13 2019-02-05 我希望增效剂公司 新阳离子肽spr741对抗生素活性的增效作用
CN114788814B (zh) * 2021-01-26 2023-10-13 浙江创新生物有限公司 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE32333E (en) 1978-10-16 1987-01-20 Eli Lilly And Company A-21978 Antibiotics and process for their production
USRE32455E (en) 1978-10-16 1987-07-07 Eli Lilly And Company A-21978 antibiotics and process for their production
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
US4524135A (en) 1982-05-21 1985-06-18 Eli Lilly And Company A-21978C cyclic peptides
USRE32311E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
USRE32310E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4885243A (en) 1984-10-09 1989-12-05 Eli Lilly And Company Process for producing A-21978C derivatives
US4800157A (en) 1985-09-09 1989-01-24 Eli Lilly And Company Process for producing the A-21978C antibiotics
US4874843A (en) 1987-12-03 1989-10-17 Eli Lilly And Company Chromatographic purification process
CA1315229C (en) 1987-06-10 1993-03-30 Patrick J. Baker Chromatographic purification process
ZA901622B (en) * 1989-03-06 1991-11-27 Lilly Co Eli An improved diluent formulation for daptomycin
FR2755857B1 (fr) * 1996-11-19 1998-12-24 Rhone Poulenc Rorer Sa Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
FR2772272B1 (fr) * 1997-12-16 2000-01-14 Rhone Poulenc Rorer Sa Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
EP1115417B1 (en) 1998-09-25 2006-04-05 Cubist Pharmaceuticals, Inc. Use of daptomycin
US9393093B2 (en) 2008-02-18 2016-07-19 Covidien Lp Clip for implant deployment device

Also Published As

Publication number Publication date
NO20011454L (no) 2001-05-25
JP4184607B2 (ja) 2008-11-19
WO2000018419A3 (en) 2000-07-06
CN1348382A (zh) 2002-05-08
WO2000018419A2 (en) 2000-04-06
JP2003321389A (ja) 2003-11-11
LU91254I2 (fr) 2006-08-28
KR20010075327A (ko) 2001-08-09
IS8807A (is) 2009-03-10
US6468967B1 (en) 2002-10-22
CY2006003I1 (el) 2009-11-04
CY2006003I2 (el) 2009-11-04
EP1674107A2 (en) 2006-06-28
NZ510690A (en) 2002-10-25
RU2363489C2 (ru) 2009-08-10
CA2344318C (en) 2006-07-04
DE122006000049I2 (de) 2007-11-08
NL300232I2 (nl) 2007-01-02
JP2002525335A (ja) 2002-08-13
HK1040363B (zh) 2007-01-26
KR20100051735A (ko) 2010-05-17
NL300232I1 (nl) 2006-09-01
CA2344318A1 (en) 2000-04-06
PT1674107T (pt) 2016-12-07
PT1115417E (pt) 2006-07-31
PL203689B1 (pl) 2009-11-30
EP1674107A3 (en) 2012-06-20
US20020142948A1 (en) 2002-10-03
ES2603086T3 (es) 2017-02-23
DE122006000049I1 (de) 2007-01-04
AU764348B2 (en) 2003-08-14
BR9914051A (pt) 2001-06-19
DE69930758D1 (de) 2006-05-18
JP2004339238A (ja) 2004-12-02
PL206091B1 (pl) 2010-06-30
ES2259845T3 (es) 2006-10-16
PL348328A1 (en) 2002-05-20
DK1674107T3 (en) 2016-12-19
IS5890A (is) 2001-03-14
ATE322280T1 (de) 2006-04-15
RU2363489C9 (ru) 2010-03-20
HUP0103874A2 (hu) 2002-02-28
SI1674107T1 (sl) 2017-01-31
RU2004106569A (ru) 2005-08-10
US6852689B2 (en) 2005-02-08
DE69930758T2 (de) 2007-04-26
EP1674107B8 (en) 2017-01-25
HU230656B1 (hu) 2017-06-28
JP2006335773A (ja) 2006-12-14
CN1150029C (zh) 2004-05-19
EP1674107A8 (en) 2006-10-04
DK1115417T3 (da) 2006-07-31
AU6268799A (en) 2000-04-17
EP1115417B1 (en) 2006-04-05
EP1674107B1 (en) 2016-08-24
TR200100841T2 (tr) 2002-01-21
NO20011454D0 (no) 2001-03-22
CY1118334T1 (el) 2017-06-28
EP1115417A2 (en) 2001-07-18
CN1530136A (zh) 2004-09-22
HK1040363A1 (en) 2002-06-07
HUP0103874A3 (en) 2002-09-30
SI1115417T1 (sl) 2006-08-31

Similar Documents

Publication Publication Date Title
CY1105556T1 (el) Χρηση δαπτομυκινης
CY1107103T1 (el) Νεα παραγωγα νουκλεοζιτων με τροποποιημενη με καρβοξαμιδινη μονοκυκλικη βαση
CY1118206T1 (el) Φαρμακευτικη συνθεση για δερματικη χρηση για να θεραπευεται ψωριαση που περιλαμβανει καλσιποτριολη και βηταμεθαζονη
CY1124763T1 (el) Μεθοδος για την θεραπευτικη αντιμετωπιση της πρωτοπαθους αϋπνιας
GT199700095A (es) Derivados 6,5-heterobiciclicos sustituidos.
ATE284413T1 (de) Therapeutische peptid derivate
CY1110405T1 (el) Φαρμακευτικες συνθεσεις περιλαμβανοντας δεξτρομεθορφανη και κινιδινη για την αγωγη νευρολογικων διαταραχων
CY1106674T1 (el) Αζαδικυκλικοι ετεροκυκλοι σαν ρυθμιστες υποδοχεα κανναβινοειδους
CY1105120T1 (el) Η αντιμετωπιση αναπνευστικων νοσων
CY1106679T1 (el) Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα
ATE245977T1 (de) Therapeutische substituierte guanidine
CY1105235T1 (el) Συνθεσεις λασοφοξιφενης
DK0825857T3 (da) Anvendelse af gabapentin og derivater deraf til behandling af mani og bipolær lidelse
SE0004054D0 (sv) N-type calcium channel antagonists for the treatment of pain
UY26376A1 (es) Combinaciones sinteticas de un antagonista de nk1 y un analogo estructural de gaba
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
HUP9900504A2 (en) Use of insect pheromones for producing pharmaceutical compositions having antiglucocorticoid effect
ES2063079T3 (es) Una composicion farmaceutica que tiene efecto sinergico basada en sulbactam y metampicilina.